Clinical Trial Update: Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder [Phase 3]

View source ↗

Summary

Phase 3 safety and tolerability trial of lumateperone (Caplyta) in pediatric patients with schizophrenia, bipolar disorder, or autism spectrum disorder, current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Caplyta (lumateperone)

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Schizophrenia, Bipolar Disorder | Phase 3 | Status: RECRUITING